Published Studies

The Science Behind the Method

Key Publications

  • Bale, Bradley Field, Doneen, Amy Lynn, Leimgruber, Pierre P, Vigerust, David John. (2022) Atherosclerosis and Vascular Medicine: The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. Frontiers in Cardiovascular Medicine. November 09, 2022 – LINK
  • Doneen, Amy Lynn, Bale, Bradley Field, Vigerust, David John (2020) Cardiovascular Prevention: Migrating from a Binary to a Ternary Classification. Frontiers in Cardiovascular Medicine. May 22 2020
  • Cheng, H.G., B.S. Patel, S.S. Martin, M. Blaha, A. Doneen, B.Bale and S.R. Jones (2016). Effect of comprehensive cardiovascular disease risk management on longitudinal changes in carotid artery intima-media thickness in a community based prevention clinic. Archives of Medical Science 12(4):728-735.
  • Feng, D., Esperat, M. C., Doneen, A. L., Bale, B., Song, H., & Green, A. E. (2015). Eight-year outcomes of a program for early prevention of cardiovascular events: a growth-curve analysis. J Cardiovasc Nurs, 30(4), 281-291.
  • Bale, B. F., Doneen, A.L., Drueding, R., &Charland, S.L. (2006). Aggressive risk factor modification in patients with sub-clinical atherosclerosis reduces plaque burden and regresses carotid artery wall thicknessAtherosclerosis7(3), 161.
  • Doneen, A. L., Bale, B. F., Charland, S. L., & Smith, T.F. (2006). Carotid Intima-media thickness testing identifies at risk patients missed by Framingham 10-year risk scoringAtherosclerosis, 7(3), 324.

Books

2022

  • Bradley Bale, MD, Amy Doneen, DNP, Lisa Collier Cool (2022) “Healthy Heart, Healthy Brain” Little, Brown Spark

2014

  • Bradley Bale, MD, Amy Doneen, ARNP, Lisa Collier Cool (2014) “Beat the Heart Attack Gene” Turner Publishing

Additional Publications by Date

2024

  •  Mewborn, E. K., Tolley, E. A., Wright, D. B., Doneen, A. L., Harvey, M., & Stanfill, A. G. (2024). Haptoglobin genotype is a risk factor for coronary artery disease in prediabetes: A case-control studyAmerican Journal of Preventive Cardiology, 17, Article 100625

2023

  • Research Features. (July 26, 2023 ). BaleDoneen method ushers in a cure to bring an end to cardiovascular disease. Retrieved July 11, 2024, from https://researchfeatures.com/baledoneen-method-ushers-cure-bring-end-cardiovascular-disease/
  •  Mewborn, E. K., Tolley, E. A., Wright, D. B., Doneen, A. L., Harvey, M., & Stanfill, A. G. (2024). Haptoglobin genotype is a risk factor for coronary artery disease in prediabetes: A case-control studyAmerican Journal of Preventive Cardiology, 17, Article 100625
  • Miller, C. S., Kryscio, R. J., Doneen, A. L., & Bale, B. F. (2023). Myeloperoxidase: A circulating marker of inflammation and tooth infectionThe American Journal of Medicine, 136(4)

2022

  • Bale, Bradley Field, Doneen, Amy Lynn, Leimgruber, Pierre P, Vigerust, David John. (2022) Atherosclerosis and Vascular Medicine: The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. Frontiers in Cardiovascular Medicine. November 09, 2022 – LINK

2020

  • Doneen, Amy Lynn, Bale, Bradley Field, Vigerust, David John (2020) Microvascular disease confers additional risk to COVID-19 infection. Medical Hypotheses. June 15 2020
  • Doneen, Amy Lynn, Bale, Bradley Field, Vigerust, David John (2020) Cardiovascular Prevention: Migrating from a Binary to a Ternary Classification. Frontiers in Cardiovascular Medicine. May 22 2020

2018

  • Bale, B.F., Doneen A.D., Vigerust, D.J. (2018) Precision Healthcare of Type 2 Diabetic Patients Through Implementation of Haptoglobin Genotyping. Frontiers of Cardiovascular Medicine October 16, 2018
  • Amy L. Doneen& Bradley F. Bale (2018) The BaleDoneen Method (BDM):A disease-inflammation approach to achieve arterial wellness, CRANIO®, 36:4, 209-210, DOI:10.1080/08869634.2018.1479491

2015

  • Feng, D., Esperat, M. C., Doneen, A. L., Bale, B., Song, H., & Green, A. E. (2015). Eight-year outcomes of a program for early prevention of cardiovascular events: a growth-curve analysis. J Cardiovasc Nurs, 30(4), 281-291.

2014

  • Doneen, A.L., Dupler, A., &Crogan, A. Why the RDH is a critical member of the health-care team. Registered Dental Hygiene Program. February 2014
  • Doneen, A.L. The direct program: A disease/inflammatory vs risk factor evaluation cardiovascular testing program.  The International Journal of Nursing & Clinical Practices. December 24, 2014.
  • Doneen, A.L., Dupler, A., &Crogan, N. Cardiovascular wellness and optimal oral health: A symbiotic relationship. Heart Health. November 26, 2014.
  • Bale, B., Doneen. A. A guarantee of arterial wellness; new era of cardiovascular medicine. Clinical & Experimental Cardiology. 2014. Bale BF, Doneen AL (2014) A Guarantee of Arterial Wellness: New Era of Cardiovascular Medicine. J Clin Exp Cardiolog 5:298.

2013

  • Doneen, A. L., & Bale, B.F. (2013). Carotid intima-media thickness testing as an asymptomatic cardiovascular disease identifier and method for making therapeutic decisionsPostgraduate Medicine125(2),108–23. 2013 doi:10.3810/pgm.2013.03.2645.
  • Doneen, A. L., & Bale, B. F. (2013). Autophagy, senescence, and arterial inflammation: relationship to arterial health and longevityAlternative Therapies in Health and Medicine19(4), 8–10.

2012

  • Mason, C. M., & Doneen, A. L. (2012). Niacin—A critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular diseaseJournal of Cardiovascular Nursing27(4), 303–316.  doi:10.1097/JCN.0b013e31821bf93f
  • Nabors, T., Bale, B., & Doneen, A. (2012). Inculpatory evidence: periodontal disease assessment and treatment is an essential element in cardiovascular wellness programsDental Economics102(9), 99.

2011

  • Jones, P. H., Bale, B., & Doneen, A. (2011). Clinician perspective on the benefits of niacin therapy for the treatment of dyslipidemia and strategies to improve long-term adherence to therapyThe Medical Roundtable—Cardiovascular Edition2(4): 249–55.
  • Taylor, A. J., Olendorf, M. W., DeMichele, M., Doneen, A. L., Faulkner, D. A., Sutton-Tyrell, K. (2011). Appropriate use criteria for carotid intima media thickness testing.

2010

  • Society of Atherosclerosis Imaging and Prevention, developed in collaboration with the International Atherosclerosis SocietyAtherosclerosis214(1): 43–46. doi:10.1016/j.atherosclerosis.2010.10.045
  • Carotid Intima-Media Thickness:  Knowledge and Application to Everyday Practice.” Bale, B. F., Cobble, M. Postgraduate Medicine.January 2010.  122(1): 7-15.
  • Optimizing Hypertension Management in Underserved Rural Populations.” Bale, B. F. Journal of National Medical Association. Jan. 2010. 102 (1): 10-17.

2009

  • Bale, B., Doneen, A., & Wegner, M. (2009). The identification of occult cardiovascular disease through the use of a novel biomarker: a case reportJournal of Clinical Lipidology3(5), 351–54. doi:10.1016/j.jacl.2009.08.004
  • Reduce Your Risk of ‘Secret’ Strokes!” Bale, B. F. Women’s World, Oct. 5, 2009, p. 15.
  • Markers of Arterial Inflammation.” August 31, 2009, Bale, B. F. Physician’s Weekly, Vol. XXVI Issue No. 33.
  • Arterial Inflammation Biomarkers,” [Cover story], Bale, B. F. ADVANCE for Administrators of the Laboratory, July 2009.

2006

  • Bale, B. F., Doneen, A.L., Drueding, R., &Charland, S.L. (2006). Aggressive risk factor modification in patients with sub-clinical atherosclerosis reduces plaque burden and regresses carotid artery wall thicknessAtherosclerosis7(3), 161.
  • Doneen, A. L., Bale, B. F., Charland, S. L., & Smith, T.F. (2006). Carotid intima-media thickness testing identifies at risk patients missed by Framingham 10-year risk scoring. Atherosclerosis, 7(3), 324.